Cited 20 times in
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2017-02-24T08:12:44Z | - |
dc.date.available | 2017-02-24T08:12:44Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0008-543X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/146584 | - |
dc.description.abstract | BACKGROUND: Vascular endothelial growth factor (VEGF)-targeted therapies are standard treatment for metastatic renal cell carcinoma (mRCC); however, toxicities can lead to drug discontinuation, which can affect patient outcomes. This study was aimed at identifying risk factors for toxicity and constructing the first model to predict toxicity-related treatment discontinuation (TrTD) in mRCC patients treated with VEGF-targeted therapies. METHODS: The baseline characteristics, treatment outcomes, and toxicity data were collected for 936 mRCC patients receiving first-line VEGF-targeted therapy from the International Metastatic Renal Cell Carcinoma Database Consortium. A competing risk regression model was used to identify risk factors for TrTD, and it accounted for other causes as competing risks. RESULTS: Overall, 198 (23.8%) experienced TrTD. Sunitinib was the most common VEGF-targeted therapy (77%), and it was followed by sorafenib (18.4%). The median time on therapy was 7.1 months for all patients and 4.4 months for patients with TrTD. The most common toxicities leading to TrTD included fatigue, diarrhea, and mucositis. In a multivariate analysis, significant predictors for TrTD were a baseline age ≥60 years, a glomerular filtration rate (GFR) <30 mL/min/1.73 m(2) , a single metastatic site, and a sodium level <135 mmol/L. A risk group model was developed that used the number of patient risk factors to predict the risk of TrTD. CONCLUSIONS: In the largest series to date, age, GFR, number of metastatic sites, and baseline sodium level were found to be independent risk factors for TrTD in mRCC patients receiving VEGF-targeted therapy. Based on the number of risk factors present, a model for predicting TrTD was built to be used as a tool for toxicity monitoring in clinical practice. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.format.extent | 411~419 | - |
dc.language | English | - |
dc.publisher | Wiley | - |
dc.relation.isPartOf | CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Aged, 80 and over | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage* | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects* | - |
dc.subject.MESH | Bevacizumab/administration & dosage | - |
dc.subject.MESH | Bevacizumab/adverse effects | - |
dc.subject.MESH | Carcinoma, Renal Cell/blood | - |
dc.subject.MESH | Carcinoma, Renal Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Renal Cell/metabolism | - |
dc.subject.MESH | Carcinoma, Renal Cell/secondary | - |
dc.subject.MESH | Databases, Factual | - |
dc.subject.MESH | Diarrhea/chemically induced | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Fatigue/chemically induced | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hand-Foot Syndrome/etiology | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Imidazoles/administration & dosage | - |
dc.subject.MESH | Imidazoles/adverse effects | - |
dc.subject.MESH | Indazoles/administration & dosage | - |
dc.subject.MESH | Indazoles/adverse effects | - |
dc.subject.MESH | Indoles/administration & dosage | - |
dc.subject.MESH | Indoles/adverse effects | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Kidney Neoplasms/blood | - |
dc.subject.MESH | Kidney Neoplasms/drug therapy* | - |
dc.subject.MESH | Kidney Neoplasms/metabolism | - |
dc.subject.MESH | Kidney Neoplasms/pathology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Models, Statistical* | - |
dc.subject.MESH | Molecular Targeted Therapy/adverse effects* | - |
dc.subject.MESH | Molecular Targeted Therapy/methods | - |
dc.subject.MESH | Mucositis/chemically induced | - |
dc.subject.MESH | Niacinamide/administration & dosage | - |
dc.subject.MESH | Niacinamide/adverse effects | - |
dc.subject.MESH | Niacinamide/analogs & derivatives | - |
dc.subject.MESH | Phenylurea Compounds/administration & dosage | - |
dc.subject.MESH | Phenylurea Compounds/adverse effects | - |
dc.subject.MESH | Predictive Value of Tests | - |
dc.subject.MESH | Pyrimidines/administration & dosage | - |
dc.subject.MESH | Pyrimidines/adverse effects | - |
dc.subject.MESH | Pyrroles/administration & dosage | - |
dc.subject.MESH | Pyrroles/adverse effects | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Sulfonamides/administration & dosage | - |
dc.subject.MESH | Sulfonamides/adverse effects | - |
dc.subject.MESH | Vascular Endothelial Growth Factor A/drug effects* | - |
dc.title | Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium | - |
dc.type | Article | - |
dc.publisher.location | United States | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Marina D. Kaymakcalan | - |
dc.contributor.googleauthor | Wanling Xie | - |
dc.contributor.googleauthor | Laurence Albiges | - |
dc.contributor.googleauthor | Scott A. North | - |
dc.contributor.googleauthor | Christian K. Kollmannsberger | - |
dc.contributor.googleauthor | Martin Smoragiewicz | - |
dc.contributor.googleauthor | Nils Kroeger | - |
dc.contributor.googleauthor | J. Connor Wells | - |
dc.contributor.googleauthor | Sun-Young Rha | - |
dc.contributor.googleauthor | Jae Lyun Lee | - |
dc.contributor.googleauthor | Rana R. McKay | - |
dc.contributor.googleauthor | Andre P. Fay | - |
dc.contributor.googleauthor | Guillermo De Velasco | - |
dc.contributor.googleauthor | Daniel Y. C. Heng | - |
dc.contributor.googleauthor | Toni K. Choueiri | - |
dc.identifier.doi | 10.1002/cncr.29773 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00434 | - |
dc.identifier.eissn | 1097-0142 | - |
dc.identifier.pmid | 26540173 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1002/cncr.29773/abstract | - |
dc.subject.keyword | International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) | - |
dc.subject.keyword | VEGF-targeted therapies | - |
dc.subject.keyword | model | - |
dc.subject.keyword | renal cell carcinoma | - |
dc.subject.keyword | risk factors | - |
dc.subject.keyword | toxicity | - |
dc.subject.keyword | treatment discontinuation | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.citation.volume | 122 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 411 | - |
dc.citation.endPage | 419 | - |
dc.identifier.bibliographicCitation | CANCER, Vol.122(3) : 411-419, 2016 | - |
dc.date.modified | 2017-02-24 | - |
dc.identifier.rimsid | 46393 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.